Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triple therapy for anti-MDA5+ dermatomyositis
NCT05375435Phase 4Unknown
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Jan 2022
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of cyclophosphamide in dermatomyositis (DM), interstitial lung disease (ILD), sponsored by Jiangsu Provincial People's Hospital. Status: unknown.
02
Drugs
cyclophosphamide
03
Conditions
dermatomyositis (DM)interstitial lung disease (ILD)
Beyond the preview
Go deeper on NCT05375435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05375435.